The drug "Madopar" describes the instructions for use as a combination agent designed to treat Parkinson's disease. Taking this drug effectively eliminates muscle stiffness, hypokinesia and dysphagia. In addition, the drug "Madopar" quickly copes with salivation and tremors. The pronounced effect of the use of this anti-Parkinsonian drug is noted six to eight days after the start of administration, and the maximum result is twenty-five to thirty days. It should be especially noted that this medicine stimulates the evacuation of the contents of the stomach well, which ultimately allows you to achieve its highest concentration in plasma in just three hours.
The combined product "Madopar" is produced (instructions for use are always included) in the form of tablets, instant tablets and capsules. The latter have a solid gelatinous structure and pink-blue body.
Each capsule contains levodopa and benserazide, which act as active components. Madopar tablets are flat-cylindrical dragees of a pale red color with a faint odor. They also include substances such as levodopa and benserazide.
Instructions for use advise you to prescribe the combined drug "Madopar" mainly for the treatment of people suffering from Parkinson's disease. In addition, this remedy is often prescribed to eliminate restless legs syndrome. Finally, using this medicine is recommended for people with kidney failure.
As for the main contraindications, Madopar tablets and capsules are strictly forbidden by the instructions for use in those patients who have serious heart diseases, angle-closure glaucoma or mental disorders. In addition, doctors do not recommend the use of this anti-Parkinsonian drug in case of decompensated disorders of the liver, kidneys or endocrine system. It is also strictly forbidden to prescribe this medicine to people under the age of twenty-five.
If the patient has an allergic reaction to levodopa or benserazide, likewise, do not start taking Madopar tablets. Reviews, like the instruction, indicate the undesirability of administering this combination drug to people with bronchial asthma. With great care, taking this antiparkinsonian drug is necessary for patients with active peptic ulcer. The drug "Madopar" should not be used in case of severe inhibition of bone marrow hematopoiesis, with melanoma, pregnancy or osteomalacia. The lactation period, arrhythmia and myocardial infarction are also included in the list of direct contraindications.
In addition to all of the above, it should be said about the possible side effects and undesirable reactions that can be triggered by taking Madopar tablets. So, for example, in the first days of treatment, there is sometimes a decrease in appetite, epigastric pain, dysphagia and vomiting. There is also a small risk of developing orthostatic hypotension, thrombocytopenia, leukopenia, hemolytic anemia or tachycardia. In addition, some patients complain of depression, sleep disturbance, insomnia, constipation, and weight gain.